Alkermes plc. Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Alkermes plc. (ALKS) had Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized of 11.10 million shares as of 2018-12-31, per its 10-K filed 2019-02-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized · last filed 2019-02-15
- 2018-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 11.10M shares.
- 2017-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 9.50M shares.
- 2016-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 11.30M shares.
- 2015-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 6.90M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized as first filed |
|---|---|---|
| 2018-12-31 | 11.10M shares 10-K · filed 2019-02-15 | |
| 2017-12-31 | 9.50M shares 10-K · filed 2018-02-16 | |
| 2016-12-31 | 11.30M shares 10-K · filed 2017-02-17 | |
| 2015-12-31 | 6.90M shares 10-K · filed 2016-02-25 | |
| 2013-12-31 | 10.00M shares 10-K · filed 2015-02-24 | 10.40M shares 10-KT · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |